This symposium will provide heart failure specialists and care providers insights into the recent guidelines for the management of obstructive hypertrophic cardiomyopathy (HCM) from the ACC/AJA and the European Society of Cardiology.  Specifically, the appropriate and practical use of cardiac myosin inhibitors in clinical practice will be highlighted by a diverse group of HCM specialists.

Agenda: 

• Introduction
• Guideline update on the treatment of obstructive HCM
• Major findings from randomized trials of cardiac myosin inhibitors (CMIs)
• Real world use of CMI in clinical practice:  What I've learned
• Key role of cardiac imaging in treatment selection

Faculty:

• Andrew Wang, MD, FACC, FAHA  Duke University School of Medicine, Durham, NC
• Carolyn Ho, MD, Brigham and Women’s Hospital, Boston, MA
• Matthew Martinez, MD, Atlantic Health System- Morristown Medical Center, Morristown, NJ
• Milind Desai, MD, MBA, FACC, FAHA, FESC, Cleveland Clinic, Cleveland, OH
• Anjali Tiku Owens, MD, Philadelphia, PA

CE credit 1.0 CME